Cara Therapeutics Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cara Therapeutics stock.
View analyst ratings for Cara Therapeutics or view top-rated stocks.

Wall Street analysts have given Cara Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cara Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Cara Therapeutics.

Cara Therapeutics will be holding an earnings conference call on Monday, August 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Cara Therapeutics, Inc. (NASDAQ:CARA) released its quarterly earnings data on Sunday, May, 9th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.12. The biopharmaceutical company had revenue of $1.94 million for the quarter, compared to analysts' expectations of $10.15 million. Cara Therapeutics had a net margin of 10.88% and a trailing twelve-month return on equity of 7.50%.
View Cara Therapeutics' earnings history.

Cara Therapeutics' stock was trading at $13.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CARA stock has decreased by 6.9% and is now trading at $12.50.
View which stocks have been most impacted by COVID-19.

3 analysts have issued 12 month price targets for Cara Therapeutics' shares. Their forecasts range from $16.00 to $30.00. On average, they expect Cara Therapeutics' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 92.0% from the stock's current price.
View analysts' price targets for Cara Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Cara Therapeutics include Prothena (PRTA), Atea Pharmaceuticals (AVIR), Rocket Pharmaceuticals (RCKT), ATA (ATAI), Zentalis Pharmaceuticals (ZNTL), Nuvation Bio (NUVB), Cytokinetics (CYTK), Arcus Biosciences (RCUS), Ironwood Pharmaceuticals (IRWD), Revance Therapeutics (RVNC), Protagonist Therapeutics (PTGX), Morphic (MORF), Global Blood Therapeutics (GBT), Organogenesis (ORGO) and Myovant Sciences (MYOV).
View all of CARA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), (CGC), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), 22nd Century Group (XXII), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Cara Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include C WorldWide Group Holding A S (1.17%), Pinnacle Associates Ltd. (0.70%), Rhumbline Advisers (0.30%), Davy Global Fund Management Ltd (0.15%), Alliancebernstein L.P. (0.11%) and Russell Investments Group Ltd. (0.10%). Company insiders that own Cara Therapeutics stock include Christopher Posner, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Mani Mohindru, Martin Vogelbaum and Scott Terrillion.
View institutional ownership trends for Cara Therapeutics.

CARA stock was sold by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Victory Capital Management Inc., Russell Investments Group Ltd., Rathbone Brothers plc, Arizona State Retirement System, Advisor Group Holdings Inc., Freedman Financial Associates Inc., and Rothschild Investment Corp IL. Company insiders that have sold Cara Therapeutics company stock in the last year include Christopher Posner, Derek T Chalmers, Frederique PhD Menzaghi, Joana Goncalves, Martin Vogelbaum, and Scott Terrillion.
View insider buying and selling activity for Cara Therapeutics or view top insider-selling stocks.

CARA stock was acquired by a variety of institutional investors in the last quarter, including Rhumbline Advisers, Exchange Traded Concepts LLC, Texas Permanent School Fund, State of Alaska Department of Revenue, Davy Global Fund Management Ltd, Oregon Public Employees Retirement Fund, 6 Meridian, and Handelsbanken Fonder AB.
View insider buying and selling activity for Cara Therapeutics or or view top insider-buying stocks.

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CARA stock can currently be purchased for approximately $12.50.

Cara Therapeutics has a market capitalization of $625.65 million and generates $135.08 million in revenue each year. The biopharmaceutical company earns $8.41 million in net income (profit) each year or $0.18 on an earnings per share basis.

Cara Therapeutics employs 80 workers across the globe.

The official website for Cara Therapeutics is www.caratherapeutics.com.

Cara Therapeutics is headquartered at 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902.

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700 or via email at [email protected]